The relationship of the interleukin-6 -174 G>C gene polymorphism with oxidative stress markers in Turkish polycystic ovary syndrome patients

Journal of Endocrinological Investigation

Volumn 31, Issue 7, 2008, Pages 624-629

  Erdogan, M ^a   Karadeniz, M ^a   Berdeli, A ^b   Alper, G ^a   Caglayan, O ^c   Yilmaz, C ^a  

^a EGE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^b Laboratory of Molecular Medicine   (Turkey)

^c KIRIKKALE UNIVERSITY   (Turkey)

Author keywords

Interleukin 6 gene polymorphism; Oxidative stress markers; Polycystic

Indexed keywords

CHOLESTEROL; CYTOSINE; DISULPHITE; GUANINE; INSULIN; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN; MALONALDEHYDE; NITRIC OXIDE; SULFITE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENE FREQUENCY; GENE LOCATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENOTYPE; HEREDITY; HUMAN; HUMAN TISSUE; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; METABOLIC PARAMETERS; OVARY POLYCYSTIC DISEASE; OXIDATIVE STRESS; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK FACTOR; TRIACYLGLYCEROL BLOOD LEVEL; TURKEY (REPUBLIC);

EID: 54949126723     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03345614     Document Type: Article

References (55)

1. King J. Polycystic ovary syndrome. J Midwifery Womens Health 2006, 51: 415-22.
2. Otto-Buczkowska E, Jarosz-Chobot P, Deja G. [Early metabolic abnormalities - insulin resistance, hyperinsulinemia, impaired glucose tolerance and diabetes, in adolescent girls with polycystic ovarian syndrome]. Przegl Lek 2006, 63: 234-8.
3. Cibula D, Cifková R, Fanta M, Poledne R, Zivny J, Skibová J. Increased risk of non-insulin dependent diabetes mellitus, arterial hypertension and coronary artery disease in perimenopausal women with a history of polycystic ovary syndrome. Hum Reprod 2000, 15: 785-9.
4. Wild RA, Painter PC, Coulson PB, Carruth KB, Ranney GB. Lipoprotein lipid concentration and cardiovascular risk in women witn polycystic ovary syndrome. J Clin Endocrinol Metab 1985, 61: 946-51.
5. Boulman N, Levy Y, Leiba R, et al. Increased C-reactive protein levels in the polycystic ovary syndrome: a marker of cardiovascular disease. J Clin Endocrinol Metab 2004, 89: 2160-5.
6. Orio F, Palomba S, Di Blase S, et al. Homocysteine levels and C677T polymorphism of methylenetetrahydrofolate reductase in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003, 88: 673-9.
7. Diamanti-Kandarakis E, Spina G, Kouli C, Migdalis I. Increased endothelin-1 levels in women with polycystic ovary syndrome and the beneficial effect of metformin therapy. J Clin Endocrinol Metab 2001, 86: 4666-73.
8. Kotur-Stevuljevic J, Memon L, Stefanovic A, et al. Correlation of oxidative stress parameters and inflammatory markers in coronary artery disease patients. Clin Biochem 2006, Sep 30; doi:10.1016/ j.clinbiochem.2006.09.007
9. Landmesser U, Harrison DG, Drexler H. Oxidant stress-a major cause of reduced endothelial nitric oxide availability in cardiovascular disease. Eur J Clin Pharmacol 2006, 62: 13-9.
10. Li H, Junk P, Huwiler A, et al. Dual effect of ceramide on human endothelial cells: induction of oxidative stress and transcriptional upregulation of endothelial nitric oxide synthase. Circulation 2002, 106: 2250-6. 11 Halcox JP, Schenke WH, Zalos G, et al. Prognostic value of coronary vascular endothelial dysfunction. Circulation 2002, 106: 653-8.
11. Chiappelli M, Tampieri C, Tumini E, et al. Interleukin-6 gene polymorphism is an age-dependent risk factor for myocardial infarction in men. Int J Immunogenet 2005, 32: 349-53.
12. Liu Y, Berthier-Schaad Y, Fallin MD, et al. IL-6 haplotypes, inflammation, and risk for cardiovascular disease in a multiethnic dialysis cohort. J Am Soc Nephrol 2006, 17: 863-70.
13. Antonicelli R, Olivieri F, Bonafè M, et al. The interleukin-6 -174 G>C promoter polymorphism is associated with a higher risk of death after an acute coronary syndrome in male elderly patients. Int J Cardiol 2005, 103: 266-71.
14. Yamada Y, Metoki N, Yoshida H, et al. Genetic risk for ischemic and hemorrhagic stroke. Arterioscler Thromb Vasc Biol 2006, 26: 1920-5.
15. Vormittag R, Hsieh K, Kaider A, et al. Interleukin-6 and interleukin-6 promoter polymorphism (-174) G>C in patients with spontaneous venous thromboembolism. Thromb Haemost 2006, 95: 802-6.
16. Konukoglu D, Serin O, Turhan MS. Plasma total homocysteine concentrations in obese and non-obese female patients with type 2 diabetes mellitus; its relations with plasma oxidative stress and nitric oxide levels. Clin Hemorheol Microcirc 2005, 33: 41-6.
17. Keaney JF, Larson MG, Vasan RS, et al. Obesity and systemic oxidative stress - clinical correlates of oxidative stress in the Framingham Study. Arterioscl Thromb Vasc Biol 2003, 23: 434-9.
18. Ruiz MC, Medina A, Moreno JM, et al. Relationship between oxidative stress parameters and atherosclerotic signs in the carotid artery of stable renal transplant patients. Transplant Proc 2005, 37: 3796-9.
19. Slatter DA, Bolton CH, Bailey AJ. The importance of lipid-derived malondialdehyde in diabetes mellitus. Diabetologia 2000, 43: 550-7.
20. Jung HH, Choi DH, Lee SH. Serum malondialdehyde and coronary artery disease in hemodialysis patients. Am J Nephrol 2004, 24: 537-42.
21. Duman BS, Ozturk M, Yilmazeri S, Hatemi H. Thiols, malonaldehyde and total antioxidant status in the Turkish patients with type 2 diabetes mellitus. Tohoku J Exp Med 2003, 201: 147-55.
22. De Caterina R, Libby P, Peng HB, et al. Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J Clin Invest 1995, 96: 60-8.
23. Förtermann U, Closs EI, Pollock JS, et al. Nitric oxide synthase isozymes. Characterization, purification, molecular cloning, and functions. Hypertension 1994, 23: 1121-31.
24. Joannides R, Richard V, Haefeli WE, Linder L, Lüscher TF, Thuillez C. Role of basal and stimulated release of nitric oxide in the regulation of radial artery caliber in humans. Hypertension 1995, 26: 327-31.
25. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med 1993, 329: 2002-12.
26. Steinberg HO, Chaker H, Leaming R, Johnson A, Brechtel G, Baron AD. Obesity/insulin resistance is associated with endothelial dysfunction. Implication for the syndrome for insulin resistance. J Clin Invest 1996, 97: 2601-10.
27. Cook S, Scherrer U. Insulin resistance, a new target for nitric oxide-delivery drugs. Fundam Clin Pharmacol 2002, 16: 441-53.
28. Baron AD, Brechtel-Hook G, Johnson A, Hardin D. Skeletal muscle blood flow. A possible link between insulin resistance and blood pressure. Hypertension 1993, 21: 129-35.
29. Baek KJ, Thiel BA, Lucas S, Stuehr DJ. Macrophage nitric oxide synthase subunit. Purification, characterization, and role of prosthetic groups and substrate in regulating their association into a dimeric enzyme. J Biol Chem 1993, 268: 21120-9.
30. The Rotterdam ESHRE/ASRM-Sponsored PCOS consensus work-shop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004, 19: 41-7.
31. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28: 412-9.
32. Yagi K. Lipid peroxides in hepatic, gastrointestinal and pancreatic diseases, in D Armstrong (ed): Free radicals in Diagnostic Medicine. New York, NY: Plenum Press. 1994, 165-9.
33. Miranda KM, Espey MG, Wink DA. A rapid, simple spectrophometric method for simultaneous detection of nitrate and nitrite. Nitric Oxide 2001, 5: 62-71.
34. Sedlak J, Lindsay RH. Estimation of total, protein-bound and non-protein sulfhydryl groups in tissue with Ellman's reagent. Anal Biochem 1968, 25: 192-205.
35. Fernández-Real JM, Broch M, Vendrell J, Richart C, Ricart W. Interleukin-6 gene polymorphism and lipid abnormalities in healthy subjects. J Clin Endocrinol Metab 2000, 85: 1334-9.
36. Yarali H, Yildirir A, Aybar F, et al. Diastolic dysfunction and increased serum homocysteine concentrations may contribute to increased cardiovascular risk in patients with polycystic ovary syndrome. Fertil Steril 2001, 76: 511-6.
37. Paradisi G, Steinberg HO, Hempfling A, et al. Polycystic ovary syndrome is associated with endothelial dysfunction. Circulation 2001, 103: 1410-5.
38. Kelly CJ, Speirs A, Gould GW, Petrie JR, Lyall H, Connell JM. Altered vascular function in young women with polycystic ovary syndrome. J Clin Endocrinol Metab 2002, 87: 742-6.
39. Kelly CC, Lyall H, Petrie JR, Gould GW, Connell JM, Sattar N. Low grade chronic inflammation in women with polycystic ovarian syndrome. J Clin Endocrinol Metab 2001, 86: 2453-5.
40. Loverro G, Lorusso F, Mei L, Depalo R, Cormio G, Selvaggi L. The plasma homocysteine levels are increased in polycystic ovary syndrome. Gynecol Obstet Invest 2002, 53: 157-62.
41. Muneyyirci-Delale O, Nacharaju VL, Dalloul M, et al. Divalent cations in women with PCOS: implications for cardiovascular disease. Gynecol Endocrinol 2001, 15: 198-201.
42. Glueck CJ, Sieve L, Zhu B, Wang P. Plasminogen activator inhibitor activity, 4G5G polymorphism of the plasminogen activator inhibitor 1 gene, and first-trimester miscarriage in women with polycystic ovary syndrome. Metabolism 2006, 55: 345-52.
43. Escobar-Morreale HF, Villuendas G, Botella-Carretero JI, Sancho J, San Millán JL. Obesity, and not insulin resistance, is the major determinant of serum inflammatory cardiovascular risk markers in premenopausal women. Diabetologia 2003, 46: 625-33.
44. Sies H. Oxidative stress: introductory remarks. In: Oxidative Stress, edited by Sies H. New York: Academic. 1985, 1-8.
45. Sies H. Oxidative Stress: Oxidants and Antioxidants. London: Academic, 1991.
46. Walch K, Grimm C, Zeillinger R, Huber JC, Nagele F, Hefler LA. A common interleukin-6 gene promoter polymorphism influences the clinical characteristics of women with polycystic ovary syndrome. Fertil Steril 2004, 81: 1638-41.
47. Lieb W, Pavlik R, Erdmann J, et al. No association of interleukin-6 gene polymorphism (-174 G/C) with myocardial infarction or traditional cardiovascular risk factors. Int J Cardiol 2004, 97: 205-12.
48. Fleming R. The use of insulin sensitising agents in ovulation induction in women with polycystic ovary syndrome. Hormones (Athens) 2006, 5: 171-8.
49. Chen NG, Azhar S, Abbasi F, Carantoni M, Reaven GM. The relationship between plasma glucose and insulin response to oral glucose, LDL oxidation, and soluble intercellular adhesion molecule-1 in healthy volunteers. Atherosclerosis 2000, 152: 203-8.
50. Nourooz-Zadeh J, Tajaddini-Sarmadi J, McCarthy S, Betteridge J, Wolff SP. Elevated levels of authentic plasma hydroperoxides in NIDDM. Diabetes 1995, 44: 1054-8.
51. Tsimikas S, Brilakis ES, Lennon RJ, et al. Relationship of IgM and IgG autoantibodies to oxidized low density lipoprotein and apolipoprotein B100-immune complexes with angiographically determined coronary artery disease and cardiovascular events. J Lipid Res 2006, Nov 8; doi: 10.1194/ jlr.M600361-JLR200
52. Kokić AN, Stević Z, Stojanović S, et al. Biotransformation of nitric oxide in the cerebrospinal fluid of amyotrophic lateral sclerosis patients. Redox Rep 2005, 10: 265-70.
53. Kenyon NJ, Last MS, Eiserich JP, Morrissey BM, Temple LM, Last JA. Differentiation of the roles of NO from airway epithelium and inflammatory cells in ozone-induced lung inflammation. Toxicol Appl Pharmacol 2006, 215: 250-9.
54. Essah PA, Nestler JE. The metabolic syndrome in polycystic ovary syndrome. J Endocrinol Invest 2006, 29: 270-80.
55. Dandona P, Aljada A, Chaudhuri A, Mohanty P, Garg R. Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation 2005, 111: 1448-54.